surgumedВестник СурГУ. МедицинаVestnik SurGU. Meditsina2949-3447Сургутский государственный университетsurgumed-112Research ArticleМЕДИКО-БИОЛОГИЧЕСКИЕ НАУКИ. ОРИГИНАЛЬНОЕ ИССЛЕДОВАНИЕLIFE SCIENCES. ORIGINAL RESEARCHИССЛЕДОВАНИЕ МУТАГЕННОГО ПОТЕНЦИАЛА РНК-СОДЕРЖАЩЕГО ПРЕПАРАТА RN-13 В ТЕСТЕ ЭЙМСАSTUDY OF MUTAGENIC POTENTIAL OF RNA-CONTAINING DRUG RN-13 IN AMES TESTШульгауЗ. Т.ShulgauZ. T.shulgau@biocenter.kzКриворучкоТ. Н.KrivoruchkoT. N.krivoruchko@biocenter.kzТолмачеваО. В.TolmachevaO. V.tolmacheva@biocenter.kzСергазыШ. Д.SergazyS. D.shynggys.sergazy@nu.edu.kzСагиндыковаБ. А.SagindykovaB. A.sagindik.ba@mail.ruГуляевА. Е.GulyaevA. E.akin@mail.ruРГП «Национальный центр биотехнологии»РоссияNational Center for BiotechnologyRussian Federation20173112201804 (34)6771Copyright © Шульгау З.Т., Криворучко Т.Н., Толмачева О.В., Сергазы Ш.Д., Сагиндыкова Б.А., Гуляев А.Е., 20182018Шульгау З.Т., Криворучко Т.Н., Толмачева О.В., Сергазы Ш.Д., Сагиндыкова Б.А., Гуляев А.Е.Shulgau Z.T., Krivoruchko T.N., Tolmacheva O.V., Sergazy S.D., Sagindykova B.A., Gulyaev A.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.surgumed.ru/jour/article/view/112

Целью исследования явилась апробация мутагенных свойств РНК-содержащего препарата RN-13 в тесте на индукцию генных мутаций (тест Эймса) на четырех штаммах Salmonella typhimurium TA98, TA100, TA1535, TA1537. Ни для одного штамма Salmonella typhimurium не обнаружено статистически значимого дозозависимого увеличения числа колоний ревертантов в присутствии исследуемого препарата в изученном диапазоне доз от 4,0 до 40,0 мг/мл относительно базового уровня спонтанных мутаций. РНК-содержащий препарат RN-13 в исследованном диапазоне доз в отношении штаммов TA98, TA100, TA1535, TA1537 Salmonella typhimurium мутагенной активностью не обладает.

The mutagenic properties of the RNA-containing drug RN-13 were studied in the gene mutation induction test (Ames test) on four strains of Salmonella typhimurium TA98, TA100, TA1535, TA1537. No statistically significant dose-dependent increase in the number of revertant colonies was observed for any strain of Salmonella typhimurium in the presence of the study drug in the studied range of doses from 4.0 to 40.0 mg/ml relative to the baseline level of spontaneous mutations. RNA-containing drug RN-13 in the studied dose range for strains TA98, TA100, TA1535, TA1537 Salmonella typhimurium does not have mutagenic activity.

РНК-препараттест Эймсамутагенные свойстваRN-13RN-13RNA-containing drugsAmes testmutagenic propertiesReferencesDimmeler S., Nicotera P. MicroRNAs in age-related diseases // EMBO molecular medicine. 2013. Vol. 5. № 2. P. 180-190.Dimmeler S., Nicotera P. MicroRNAs in age-related diseases // EMBO molecular medicine. 2013. Vol. 5. № 2. P. 180-190.Smith-Vikos T., Slack F. J. MicroRNAs and their roles in aging // Journal of cell science. 2012. Vol. 125. P. 7-17.Smith-Vikos T., Slack F. J. MicroRNAs and their roles in aging // Journal of cell science. 2012. Vol. 125. P. 7-17.Baumann V., Winkler J. miRNA-based therapies: strategies and delivery platforms for oligonucleotide and non-oligonucleotide agents // Future medicinal chemistry. 2014. Vol. 6. № 17. P. 1967-1984.Baumann V., Winkler J. miRNA-based therapies: strategies and delivery platforms for oligonucleotide and non-oligonucleotide agents // Future medicinal chemistry. 2014. Vol. 6. № 17. P. 1967-1984.Sehgal A., Vaishnaw A., Fitzgerald K. Liver as a target for oligonucleotide therapeutics // Journal of hepatology. 2013. Vol. 59. Issue 6. P. 1354-1359.Sehgal A., Vaishnaw A., Fitzgerald K. Liver as a target for oligonucleotide therapeutics // Journal of hepatology. 2013. Vol. 59. Issue 6. P. 1354-1359.Zeliadt N. Big pharma shows signs of renewed interest in RNAi drugs // Nature Medicine. 2014. Vol. 20. № 2. P.109.Zeliadt N. Big pharma shows signs of renewed interest in RNAi drugs // Nature Medicine. 2014. Vol. 20. № 2. P.109.Stommel G., Schuehlein S., Schuehlein K. H., Rainsford K. D. Therapeutic Effects of Ribunucleinate (Ribonucleotides) in Immuno-Inflammatory and Arthritic Diseases // Prog Drug Res. 2015. Vol. 70. P. 35-89.Stommel G., Schuehlein S., Schuehlein K. H., Rainsford K. D. Therapeutic Effects of Ribunucleinate (Ribonucleotides) in Immuno-Inflammatory and Arthritic Diseases // Prog Drug Res. 2015. Vol. 70. P. 35-89.Sullenger B. A., Gilboa E. Emerging clinical applications of RNA // Nature. 2002. Vol. 418. P. 252-258.Sullenger B. A., Gilboa E. Emerging clinical applications of RNA // Nature. 2002. Vol. 418. P. 252-258.Coaker H. Team demonstrates the rational design of drugs from RNA sequence // Future Med Chem. 2014. Vol. 6 (5). P. 495.Coaker H. Team demonstrates the rational design of drugs from RNA sequence // Future Med Chem. 2014. Vol. 6 (5). P. 495.Ames B. N., McCann J., Yamasaki E. Methods for Detecting Carcinogens and Mutagens with the Salmonella/Mammalian-Microsome Mutagenicity // Test Mutation Res. 1975. Vol. 31. P. 347-364.Ames B. N., McCann J., Yamasaki E. Methods for Detecting Carcinogens and Mutagens with the Salmonella/Mammalian-Microsome Mutagenicity // Test Mutation Res. 1975. Vol. 31. P. 347-364.Maron D. M., Ames B. N. Revised Methods for the Salmonella Mutagenicity Test // Mutation Res. 1983. Vol. 113. P. 173-215.Maron D. M., Ames B. N. Revised Methods for the Salmonella Mutagenicity Test // Mutation Res. 1983. Vol. 113. P. 173-215.Gatehouse D., Haworth S., Cebula T., Gocke E., Kier L., Matsushima T., Melcion C., Nohmi T., Venitt S., Zeiger E. Recommendations for the Performance of Bacterial Mutation Assays // Mutation Res. 1994. Vol. 312. P. 217-233.Gatehouse D., Haworth S., Cebula T., Gocke E., Kier L., Matsushima T., Melcion C., Nohmi T., Venitt S., Zeiger E. Recommendations for the Performance of Bacterial Mutation Assays // Mutation Res. 1994. Vol. 312. P. 217-233.Flückiger-Isler S., Kamber M. Direct comparison of the Ames microplate format (MPF) test in liquid medium with the standard Ames pre-incubation assay on agar plates by use of equivocal to weakly positive test compounds // Mutation Res. 2012. Vol. 747. № 1. P. 36-45.Flückiger-Isler S., Kamber M. Direct comparison of the Ames microplate format (MPF) test in liquid medium with the standard Ames pre-incubation assay on agar plates by use of equivocal to weakly positive test compounds // Mutation Res. 2012. Vol. 747. № 1. P. 36-45.Kamber M., Flückiger-Isler S., Engelhardt G., Jaeckh R., Zeiger E. Comparison of the Ames II and traditional Ames test responses with respect to mutagenicity, strain specificities, need for metabolism and correlation with rodent carcinogenicity // Mutagenesis. 2009. Vol. 24. № 4. P. 359-366.Kamber M., Flückiger-Isler S., Engelhardt G., Jaeckh R., Zeiger E. Comparison of the Ames II and traditional Ames test responses with respect to mutagenicity, strain specificities, need for metabolism and correlation with rodent carcinogenicity // Mutagenesis. 2009. Vol. 24. № 4. P. 359-366.

The authors declare that there are no conflicts of interest present.